Sangamo Announces Global Collaboration With Novartis to Develop Genomic Medicines for Autism and Other Neurodevelopmental Disorders

Sangamo Therapeutics, Inc., a genomic medicine company, today announced on July 30th that it has executed a global licensing collaboration agreement with Novartis to develop and commercialize gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder (ASD) and other neurodevelopmental disorders. The collaboration will leverage Sangamo’s propriety genome regulation technology, zinc finger protein transcription factors (ZFP-TFs), to aim to upregulate the expression of key genes involved in neurodevelopmental disorders.

For further information, see Businesswire(https://www.businesswire.com/news/home/20200730005166/en/)

Leave a Reply

Your email address will not be published. Required fields are marked *